专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

31. 发明申请

WO2013158644A2 TARGETED THERAPEUTICS 审中-公开
标题翻译：目标治疗
公开(公告)号：WO2013158644A2
公开(公告)日：2013-10-24
申请号：PCT/US2013036783
申请日：2013-04-16
申请人： SYNTA PHARMACEUTICALS CORP
发明人： CHIMMANAMADA DINESH U , YING WEIWEN
IPC分类号： A61K47/48
CPC分类号： A61K31/565 , A61K31/167 , A61K31/185 , A61K31/4184 , A61K31/4196 , A61K31/437 , A61K31/454 , A61K31/4545 , A61K31/4745 , A61K31/496 , A61K31/506 , A61K31/513 , A61K31/519 , A61K31/58 , A61K31/704 , A61K47/54 , A61K47/545 , A61K47/55 , G01N33/57496
摘要： The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.
摘要翻译：本发明提供药物化合物，其包括与将效应子部分指向感兴趣的生物靶标的结合部分缀合的效应部分。同样，本发明提供包括化合物的组合物，试剂盒和方法（例如治疗，诊断和成像）。该化合物可被描述为蛋白质相互作用结合部分 - 药物偶联物（SDC-TRAP）化合物，其包括蛋白质相互作用结合部分和效应部分。例如，在针对治疗癌症的某些实施方案中，SDC-TRAP可包括与细胞毒性剂缀合的Hsp90抑制剂作为效应部分。

32. 发明申请

WO2015143004A9 TARGETED THERAPEUTICS 审中-公开
标题翻译：目标治疗
公开(公告)号：WO2015143004A9
公开(公告)日：2016-09-29
申请号：PCT/US2015021184
申请日：2015-03-18
申请人： SYNTA PHARMACEUTICALS CORP
发明人： CHIMMANAMADA DINESH U , YING WEIWEN
IPC分类号： A61K47/48
CPC分类号： A61K47/48061 , A61K31/167 , A61K31/337 , A61K31/357 , A61K31/4184 , A61K31/4196 , A61K31/454 , A61K31/4545 , A61K31/4745 , A61K31/513 , A61K31/519 , A61K31/58 , A61K31/704 , A61K47/481 , A61K47/545 , A61K47/55
摘要： The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.
摘要翻译：本发明提供药物化合物，其包括与将效应子部分指向感兴趣的生物靶标的结合部分缀合的效应部分。同样，本发明提供包括化合物的组合物，试剂盒和方法（例如治疗，诊断和成像）。该化合物可被描述为蛋白质相互作用结合部分 - 药物偶联物（SDC-TRAP）化合物，其包括蛋白质相互作用结合部分和效应部分。例如，在针对治疗癌症的某些实施方案中，SDC-TRAP可包括与细胞毒性剂缀合的Hsp90抑制剂作为效应部分。

33. 发明公开

EP1556140A4 NOVEL COMPOUNDS 审中-公开
标题翻译： NEUE VERBINDUNGEN
公开(公告)号：EP1556140A4
公开(公告)日：2006-04-19
申请号：EP03776373
申请日：2003-10-14
申请人： SYNTA PHARMACEUTICALS CORP
发明人： SUN LIJUN , ONO MITSUNORI , WADA YUMIKO , YING WEIWEN , PRZEWLOKA TERESA , KOSTIK ELENA
IPC分类号： A61P19/02 , A61K31/52 , A61K31/522 , A61P1/00 , A61P1/02 , A61P3/10 , A61P17/06 , C07D473/16 , C07D473/18 , C07D473/34
CPC分类号： C07D473/34 , C07D473/16 , C07D473/18
摘要： This invention features a compound of formula (I): R1 is aryl or heteroaryl; each of R2 and R4, independently, is H, halogen, CN, alkyl, ORa, or NRaRb; R3 is H, halogen, CN, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, ORa, OC(O)Ra, OC(O)NRaRb, NRaRb, NRaC(O)Rb, NRaS(O)Rb, NRaS(O)2Rb, NRaC(O)NRbRc NRaC(S)NRbR°, NRaC(NRb)NRcRd, NRaC(O)ORb, S(O)NTRaRt, S(O)2NRSRb, S(O)Ra, S(O)2Ra, C(O)Ra, C(O)ORa, or C(O)NRaRl; R5 is H or alkyl; n is 0, 1, 2, 3, 4, 5, or 6; A is 0, S, S(O), S(O)2, or NW; B is N or CRC; X is 0, S, S(O), S(O)2, NR, or C(O); Y is a covalent bond, C(O), C=NR a, O, S, S(O), S(O)2, or NW; Z is N or CH; each of U and V, independently, is N or CR; and W is 0, S, or NR'; in which each of Ra, Rb, Re, and Rd, independently, is H, alkyl, aryl, heteroaryl, cyclyl, or heterocyclyl; Re is H, alkyl, aryl, acyl, or sufonyl; and Rf is H, alkyl., aryl, acyl, sulfonyl, alkoxyl, amino, ester, amide, CN, or halogen. The compound is useful for treating an interleukin- 12 overproduction-related disorder.
摘要翻译：本发明的特征在于式（I）的化合物：R 1是芳基或杂芳基; R 2和R 4中的每一个独立地为H，卤素，CN，烷基，ORa或NRaRb; （O）R a，OC（O）NR a R b，NR a R b，NR a C（O）R b，NR a S（O）R b，其中R b是H，卤素，CN，烷基，烯基，炔基，芳基，杂芳基，（O）2Rb，NRaC（O）NRbRc，NRaC（S）NRbR°，NRaC（NRb）NRcRd，NRaC（O）ORb，S（O）NTRaRt，S（O）2NRSRb，S（O）Ra，S O）2Ra，C（O）R a，C（O）ORa或C（O）NR a R 1; R5是H或烷基; n是0,1,2,3,4,5或6; A是O，S，S（O），S（O）2或NW; B是N或CRC; X是O，S，S（O），S（O）2，NR或C（O）; Y是共价键，C（O），C = NR a，O，S，S（O），S（O）2或NW; Z是N或CH; U和V中的每一个独立地是N或CR; 和W是0，S或NR'; 其中Ra，Rb，Re和Rd中的每一个独立地为H，烷基，芳基，杂芳基，环基或杂环基; Re是H，烷基，芳基，酰基或磺酰基; Rf为H，烷基，芳基，酰基，磺酰基，烷氧基，氨基，酯，酰胺，CN或卤素。该化合物可用于治疗白介素-12过量产生相关疾病。

34. 发明公开

EP1732900A4 ACRYLONITRILE DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES 审中-公开
标题翻译： FOR炎性和免疫特定用途的丙烯腈衍生物
公开(公告)号：EP1732900A4
公开(公告)日：2007-12-12
申请号：EP05744197
申请日：2005-03-24
申请人： SYNTA PHARMACEUTICALS CORP
发明人： CHEN SHOUJUN , YING WEIWEN , JIANG JUN , ONO MITSUNORI , SUN LIJUN
IPC分类号： C07D231/12 , A61K31/415 , A61K31/724 , A61P29/00 , C07D231/10 , C07D231/14 , C07D231/22 , C07D235/10 , C07D235/18 , C07D403/10 , C07D405/10 , C07D409/04 , C07D409/10
CPC分类号： C07D231/12 , C07D231/22 , C07D235/10 , C07D235/18 , C07D403/10 , C07D405/10 , C07D409/04 , C07D409/10

36. 发明专利

HK1207098A1 TARGETED THERAPEUTICS 未知
公开(公告)号：HK1207098A1
公开(公告)日：2016-01-22
申请号：HK15107828
申请日：2015-08-13
申请人： SYNTA PHARMACEUTICALS CORP
发明人： CHIMMANAMADA DINESH U , YING WEIWEN
IPC分类号： C07K20060101
摘要： The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.

37. 发明专利

CA2695995C TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY 未知
公开(公告)号：CA2695995C
公开(公告)日：2015-09-29
申请号：CA2695995
申请日：2008-08-13
申请人： SYNTA PHARMACEUTICALS CORP
发明人： YING WEIWEN , SUN LIJUN , KOYA KEIZO , CHIMMANAMADA DINESH U , ZHANG SHIJIE , PRZEWLOKA TERESA , LI HAO
IPC分类号： C07F9/6518 , A61K31/4196 , A61K31/5355 , C07F9/6558
摘要： The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a composition comprising such a compound.

38. 发明专利

AU2005306484C1 Triazole compounds that modulate Hsp90 activity 未知
公开(公告)号：AU2005306484C1
公开(公告)日：2015-07-23
申请号：AU2005306484
申请日：2005-11-17
申请人： SYNTA PHARMACEUTICALS CORP
发明人： YING WEIWEN , JAMES DAVID , ZHANG SHIJIE , PRZEWLOKA TERESA , CHAE JUNGHYUN , CHIMMANAMADA DINESH U , LEE CHI-WAN , KOSTIK ELENA , NG HOWARD P , FOLEY KEVIN , DU ZHENJIAN , BARSOUM JAMES
IPC分类号： C07D249/12 , A61K31/4196 , A61P35/00 , C07D401/04 , C07D403/04 , C07D405/04
摘要： The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a composition comprising such a compound.

39. 发明专利

CA2682665C TRIAZINONE AND DIAZINONE DERIVATIVES USEFUL AS HSP90 INHIBITORS 未知
公开(公告)号：CA2682665C
公开(公告)日：2015-07-21
申请号：CA2682665
申请日：2008-03-24
申请人： SYNTA PHARMACEUTICALS CORP
发明人： LEE CHI-WAN , PRZEWLOKA TERESA , YING WEIWEN , SONG MINGHU , DU ZHENJIAN , FOLEY KEVIN , ZHOU DAN , QIN SHUZHEN
IPC分类号： C07D239/10 , A61K31/4168 , A61K31/4196 , C07D249/12
摘要： The present invention relates to compounds according to formulae (IA) to (ID) and compositions that inhibit the activity of Hsp90. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a compound of the invention, or a composition comprising such a compound.

40. 发明专利

CA2677481C TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY 未知
公开(公告)号：CA2677481C
公开(公告)日：2015-07-07
申请号：CA2677481
申请日：2008-02-08
申请人： SYNTA PHARMACEUTICALS CORP
发明人： CHIMMANAMADA DINESH U , BURLISON JOSEPH A , YING WEIWEN , SUN LIJUN , SCHWEIZER STEFAN MICHAEL , ZHANG SHIJIE , DEMKO ZACHARY , JAMES DAVID , PRZEWLOKA TERESA
IPC分类号： C07D249/08 , A61K31/4196 , A61P35/00 , C07D249/10 , C07D249/12 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/04 , C07D405/14 , C07D417/14
摘要： The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to the use of a substit substituted triazole compound of the invention, or a composition comprising such a compound in the preparation of a medicament for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof. Illustrative compounds of the invention may be characterized by the compound of formula VIII: (see formula VIII)

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式